MRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients

AIDS

Volumn 26, Issue 4, 2012, Pages

  Van Gulck, Ellen ^a   Vlieghe, Erika ^b   Vekemans, Marc ^b   Van Tendeloo, Viggo F I ^c,d   Van De Velde, Ann ^c,d   Smits, Evelien ^c,d   Anguille, Sébastien ^c,d   Cools, Nathalie ^c,d   Goossens, Herman ^c   Mertens, Liesbet ^b   De Haes, Winni ^a   Wong, Johnsson ^e   Florence, Eric ^b   Vanham, Guido ^a,c,f   Berneman, Zwi N ^c,d  

^a Virology Unit   (Belgium)

^b Department of Clinical Sciences   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

dendritic cells; HIV 1; immunotherapy; mRNA electroporation; therapeutic vaccination

Indexed keywords

ANTIRETROVIRUS AGENT; DENDRITIC CELL VACCINE; GAG PROTEIN; GAMMA INTERFERON; MESSENGER RNA; NEF PROTEIN; REV PROTEIN; TRANSACTIVATOR PROTEIN;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSE; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; ELECTROPORATION; FEASIBILITY STUDY; HEMATOLOGICAL PARAMETERS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOGENICITY; IMMUNOLOGICAL PARAMETERS; IMMUNOTHERAPY; INJECTION SITE INDURATION; LYMPHOCYTE PROLIFERATION; MONOCYTE; NUCLEOTIDE SEQUENCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SKIN REDNESS; SUPERINFECTION; T LYMPHOCYTE; VACCINATION; VIRUS STRAIN;

ADULT; AIDS VACCINES; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; ELECTROPORATION; FEASIBILITY STUDIES; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV INFECTIONS; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; RECOMBINANT FUSION PROTEINS; REV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; RNA, MESSENGER; RNA, VIRAL; T-LYMPHOCYTES; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84857045791     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834f33e8     Document Type: Article

References (38)

1. Addo MM, Draenert R, Rathod A, Verrill CL, Davis BT, Gandhi RT, et al. Fully differentiated HIV-1 specific CD8R T effector cells are more frequently detectable in controlled than in progressive HIV-1 infection. PLoS ONE 2007; 2:e321.
2. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, Moodley E, et al. CD8R T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007; 13:46-53. (Pubitemid 46067385)
3. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860. (Pubitemid 28135961)
4. Chougnet C, Cohen SS, Kawamura T, Landay AL, Kessler HA, Thomas E, et al. Normal immune function of monocyte-derived dendritic cells from HIV-infected individuals: implications for immunotherapy. J Immunol 1999; 163:1666-1673. (Pubitemid 29352792)
5. Sapp M, Engelmayer J, Larsson M, Granelli-Piperno A, Steinman R, Bhardwaj N. Dendritic cells generated from blood monocytes of HIV-1 patients are not infected and act as competent antigen presenting cells eliciting potent T-cell responses. Immunol Lett 1999; 66:121-128. (Pubitemid 29136828)
6. Van Gulck ER, Ponsaerts P, Heyndrickx L, Vereecken K, Moerman F, De Roo A, et al. Efficient stimulation of HIV-1-specific T cells using dendritic cells electroporated with mRNA encoding autologous HIV-1 Gag and Env proteins. Blood 2006; 107: 1818-1827. (Pubitemid 43289359)
7. Van Gulck ER, Vanham G, Heyndrickx L, Coppens S, Vereecken K, Atkinson D, et al. Efficient in vitro expansion of HIV-specific T cell responses by gag mRNA-electroporated dendritic cells from treated and untreated HIV-1-infected individuals. J Virol 2008; 82:3561-3573. (Pubitemid 351429932)
8. Garcia F, Lejeune M, Climent N, Gil C, Alcami J, Morente V, et al. Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J Infect Dis 2005; 191:1680-1685. (Pubitemid 40656756)
9. Van Gulck E, Van Tendeloo VF, Berneman ZN, Vanham G. Role of dendritic cells in HIV-immunotherapy. Curr HIV Res 2010; 8:310-322.
10. Van Tendeloo VF, Ponsaerts P, Lardon F, Nijs G, Lenjou M, Van Broeckhoven C, et al. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 2001; 98:49-56.
11. Routy JP, Boulassel MR, Yassine-Diab B, Nicolette C, Healey D, Jain R, et al. Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy. Clin Immunol 2010; 134:140-147.
12. Verrier B. Therapeutic vaccination for chronic infectious diseases: lessons from HIV-1. J Clin Virol 2005; 34 (Suppl 1):S9-S12. (Pubitemid 43197744)
13. Addo MM, Yu XG, Rosenberg ES, Walker BD, Altfeld M. Cytotoxic T-lymphocyte (CTL) responses directed against regulatory and accessory proteins in HIV-1 infection. DNA Cell Biol 2002; 21:671-678.
14. Addo MM, Yu XG, Rathod A, Cohen D, Eldridge RL, Strick D, et al. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol 2003; 77:2081-2092. (Pubitemid 36110021)
15. Betts MR, Ambrozak DR, Douek DC, Bonhoeffer S, Brenchley JM, Casazza JP, et al. Analysis of total human immunodeficiency virus (HIV)-specific CD4(R) and CD8(R) T-cell responses: relationship to viral load in untreated HIV infection. J Virol 2001; 75:11983-11991. (Pubitemid 33115870)
16. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8R T cells. Blood 2006; 107:4781-4789. (Pubitemid 43882629)
17. Zimmerli SC, Harari A, Cellerai C, Vallelian F, Bart PA, Pantaleo G. HIV-1-specific IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells. Proc Natl Acad Sci USA 2005; 102:7239-7244. (Pubitemid 40696363)
18. Migueles SA, Laborico AC, Shupert WL, Sabbaghian MS, Rabin R, Hallahan CW, et al. HIV-specific CD8R T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 2002; 3:1061-1068. (Pubitemid 35363659)
19. Spentzou A, Bergin P, Gill D, Cheeseman H, Ashraf A, Kaltsidis H, et al. Viral inhibition assay: a CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates. J Infect Dis 2010; 201:720-729.
20. Van Tendeloo VF, Van de Velde A, Van Driessche A, Cools N, Anguille S, Ladell K, et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci USA 2010; 107:13824-13829.
21. Allard SD, Pletinckx K, Breckpot K, Heirman C, Bonehill A, Michiels A, et al. Functional T-cell responses generated by dendritic cells expressing the early HIV-1 proteins Tat, Rev and Nef. Vaccine 2008; 26:3735-3741.
22. De Keersmaecker B, Heirman C, Allard S, Bonehill A, Corthals J, Thielemans K, et al. Lumenal part of the DC-LAMP protein is not required for induction of antigen-specific T cell responses by means of antigen-DC-LAMP messenger RNAelectroporated dendritic cells. Hum Gene Ther 2010; 21:479-485.
23. Frahm N, Adams S, Kiepiela P, Linde CH, Hewitt HS, Lichterfeld M, et al. HLA-B63 presents HLA-B57/B58-restricted cytotoxic T-lymphocyte epitopes and is associated with low human immunodeficiency virus load. J Virol 2005; 79:10218-10225. (Pubitemid 41098563)
24. Janetzki S, Panageas KS, Ben-Porat L, Boyer J, Britten CM, Clay TM, et al. Results and harmonization guidelines from two largescale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother 2008; 57:303-315. (Pubitemid 350295382)
25. Resino S, Abad ML, Navarro J, Bellon JM, Sanchez-Ramon S, Angeles Munoz-Fernandez M. Stimulated proliferative responses in vertically HIV-infected children on HAART correlate with clinical and immunological markers. Clin Exp Immunol 2003; 131:130-137. (Pubitemid 36098832)
26. Beirnaert E, Willems B, Peeters M, Bouckaert A, Heyndrickx L, Zhong P, et al. Design and evaluation of an in-house HIV-1 (groupM and O), SIVmnd and SIVcpz antigen capture assay. J Virol Methods 1998; 73:65-70. (Pubitemid 28473234)
27. Miura T, Brockman MA, Brumme ZL, Brumme CJ, Pereyra F, Trocha A, et al. HLA-associated alterations in replication capacity of chimeric NL4-3 viruses carrying gag-protease from elite controllers of human immunodeficiency virus type 1. J Virol 2009; 83:140-149.
28. Sekaly RP. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med 2008; 205:7-12.
29. Gray CM, Mlotshwa M, Riou C, Mathebula T, de Assis RD, Mashishi T, et al. Human immunodeficiency virus-specific gamma interferon enzyme-linked immunospot assay responses targeting specific regions of the proteome during primary subtype C infection are poor predictors of the course of viremia and set point. J Virol 2009; 83:470-478.
30. Lieberman J. Tracking the killers: how should we measure CD8 T cells in HIV infection? AIDS 2004; 18:1489-1493. (Pubitemid 39037472)
31. Valentine LE, Piaskowski SM, Rakasz EG, Henry NL, Wilson NA, Watkins DI. Recognition of escape variants in ELISPOT does not always predict CD8R T-cell recognition of simian immunodeficiency virus-infected cells expressing the same variant sequences. J Virol 2008; 82:575-581. (Pubitemid 350309173)
32. Yang OO. Will we be able to 'spot' an effective HIV-1 vaccine? Trends Immunol 2003; 24:67-72. (Pubitemid 36120641)
33. Watkins DI. The hope for an HIV vaccine based on induction of CD8R T lymphocytes: a review. Mem Inst Oswaldo Cruz 2008; 103:119-129. (Pubitemid 351535005)
34. Lu W, Arraes LC, Ferreira WT, Andrieu JM. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 2004; 10:1359-1365. (Pubitemid 40022718)
35. Garcia F, Climent N, Assoumou L, Gil C, Gonzalez N, Alcami J, et al. A therapeutic dendritic cell-based vaccine for HIV-1 infection. J Infect Dis 2011; 203:473-478.
36. Fischer W, Perkins S, Theiler J, Bhattacharya T, Yusim K, Funkhouser R, et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med 2007; 13:100-106. (Pubitemid 46067393)
37. Barouch DH, O'Brien KL, Simmons NL, King SL, Abbink P, Maxfield LF, et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 2010; 16:319-323.
38. Santra S, Liao HX, Zhang R, Muldoon M, Watson S, Fischer W, et al. Mosaic vaccines elicit CD8R T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med 2010; 16:324-328.